Abstract: Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
January 23, 2024
Assignee:
Massachusetts Institute of Technology
Inventors:
Mark David Simon, Bradley L. Pentelute, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
Abstract: Novel methods and apparatus are disclosed for cell culture and cell recovery. The methods and apparatus simplify the process of cell separation from media, minimize potential damage to gas permeable devices during fluid handling, and allow closed system automated cell culture and cell recovery from gas permeable devices.
Abstract: [Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
January 9, 2024
Assignees:
KanonCure, Inc., National University Corporation Tottori University
Abstract: Ammonium cation detergents comprising a quaternary or tertiary ammonium cation can be used as detergents to denature proteins and are particularly useful in denaturing glycoproteins or glycopeptides prior to enzymatic deglycosylation. Ammonium cation detergents with sulfate or sulfonate anions are particularly useful.
Type:
Grant
Filed:
August 10, 2021
Date of Patent:
January 2, 2024
Assignee:
Agilent Technologies, Inc.
Inventors:
Michael J. Kimzey, Francis T. Haxo, Vaishali Sharma
Abstract: The present disclosure provides an oligopeptide FTLE isolated from chili pepper seeds, and application thereof in preventing or treating cancer, the oligopeptide is isolated from chili pepper seeds and has an anti-tumor effect, and in particular, the oligopeptide can effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.
Abstract: An organ preservation and/or perfusion solution for an isolated tissue or organ is provided. The solution comprises dextran, glucose, calcium ions, a buffer, and water, has a pH of 6.6 to 7.8, and is sterile based on having been subjected to heat sterilization. A method of preparing the solution also is provided. The method comprises combining dextran, glucose, calcium ions, buffer, and water to obtain an initial solution, adjusting the pH of the initial solution to 7.0 to 7.8 if needed, and subjecting the initial solution to heat sterilization, thereby obtaining the organ preservation and/or perfusion solution. A method of preserving and/or perfusing an isolated tissue or organ also is provided. A method for flushing, storage, and/or transportation of an isolated lung after removal from a donor in preparation for eventual transplantation into a recipient also is provided.
Abstract: A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner; wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 ?M to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
December 19, 2023
Assignees:
ST. ANNA KINDERKREBSFORSCHUNG, UNIVERSITÄT FÜR BODENKULTUR WIEN
Inventors:
Michael Traxlmayr, Christian Obinger, Charlotte Brey, Manfred Lehner
Abstract: The present invention provides a method for determining the effect of a drug on a mature cardiomyocyte. In some embodiments, the method comprises using transmembrane voltage and/or intracellular calcium data obtained from control immature cardiomyocytes and those that have been contacted with the drug to parameterize models of immature cardiomyocytes, then applying a maturation matrix to generate a mature cardiomyocyte model. The method is useful for, among other things, predicting whether a drug may have proarrhythmic properties and for determining whether a particular drug should be administered to a patient.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
December 19, 2023
Assignee:
ORGANOS, INC.
Inventors:
Aslak Tveito, Samuel Wall, Karoline Horgmo Jaeger
Abstract: The invention relates to methods for generating multipotent mammary stern cells from isolated and cultured human breast luminal cells. The method comprises the steps: 1. isolating and growing normal differentiated cells in vitro; 2. treating the differentiated cells with either a conditioned medium from active fibroblasts or cytokine. The invention also relates to multipotent mammary stem cells, cultures of the multipotent stem cells, differentiated cells, tissues, organs derived from the culture multipotent stem cells isolated by the methods disclosed and therapeutic and other uses for those cells thereof.
Type:
Grant
Filed:
August 10, 2021
Date of Patent:
December 5, 2023
Assignee:
KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
Inventors:
Abdelilah Aboussekhra, Huda H. Al-Khalaf, Hazem Ghebeh
Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion.
Type:
Grant
Filed:
July 12, 2021
Date of Patent:
November 28, 2023
Assignee:
CytoSorbents Corporation
Inventors:
Tamaz Guliashvili, Thomas Golobish, Maryann Gruda, Pamela O'Sullivan, Andrew Scheirer, Vincent Capponi, Phillip Chan, Wei-Tai Young
Abstract: The invention relates to a method of increasing the yield of virus, virus particles, or viral vectors from host cells in a bioreactor. The invention provides a reproducible and robust method and system of determining and controlling the optimal time of infection of host cells using a correlation of process air parameters including Air flow, O2 flow, and respective trends thereof resulting in increased virus yield.
Type:
Grant
Filed:
May 19, 2022
Date of Patent:
November 28, 2023
Assignee:
RESILIENCE GOVERNMENT SERVICES, INC.
Inventors:
Perry Newton, Dalton Berrie, Tyler Grow, Sheldon Doxilly, Christopher J. Montoya, Sara Jane Terpening, Eric Vela
Abstract: Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.
Abstract: Compositions including an antibiotic factor from Malassezia are provided. In some examples, the compositions include a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell and a pharmaceutically acceptable carrier. Methods of treating an infection in a subject, such as a Staphylococcus infection are also provided.
Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
November 14, 2023
Assignee:
Novartis AG
Inventors:
Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Liansheng Su, Lihua Yang, Rui Zheng
Abstract: The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.
Type:
Grant
Filed:
May 14, 2021
Date of Patent:
November 7, 2023
Assignees:
MUSC Foundation For Research Development, United States Government as Represented by the Department of Veteran Affairs
Inventors:
Stephen Tomlinson, DeAnna Adkins, Ali Alawieh
Abstract: The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.
Type:
Grant
Filed:
May 21, 2021
Date of Patent:
October 31, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Quyen T. Nguyen, Mike Whitney, Dina Hingorani, Roger Y. Tsien, Stephen Adams
Abstract: The disclosure provides a therapeutic method for preventing, ameliorating and/or treating Alzheimer's disease in a subject in need of such treatment. The therapeutic method comprises administrating to said subject a pharmaceutical combination comprising an effective amount of curcumin analog, TML-6 and an effective amount of an anti-A beta (A?) antibody.
Type:
Grant
Filed:
April 20, 2022
Date of Patent:
October 24, 2023
Assignees:
MERRY LIFE BIOMEDICAL COMPANY, LTD., NATIONAL HEALTH RESEARCH INSTITUTES
Abstract: Recombinant oncolytic viruses (OVs) that express one or more metabolic modulator proteins, such as an adipokine (e.g., leptin or chemerin), insulin, and/or IGF-1, and methods of their use to treat cancer, for example in immunotherapy anti-cancer treatments. In some examples, such recombinant OVs and methods increase T cell infiltration into the tumor or tumor microenvironment.
Type:
Grant
Filed:
January 28, 2019
Date of Patent:
October 17, 2023
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Greg M. Delgoffe, Dayana Rivadeneira, Padmavathi Sampath, Stephen H. Thorne
Abstract: The present invention provides a method of sugar-guided modifying a glycosylated polypeptide. First, a boronic acid group of a probe molecule and a sugar group of the glycosylated polypeptide form a first covalent bond. Next, an alkyne group of a modifying group and an azide group of the probe molecule form a second covalent bond by adding a promoter. As a result, the modifying group can be close to the glycosylated polypeptide. Then, the modifying group can bind to a nucleophilic residue that is near the sugar group, through a nucleophilic addition reaction. The method of the present invention can selectively modify a given site with the guidance of the sugar group.
Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
Type:
Grant
Filed:
November 3, 2021
Date of Patent:
October 10, 2023
Inventors:
Steven D Gruver, Heather Kozy, Jessica O'Rear, Barbara Rosen, Ute Schellenberger, Jun-Zhi Wei, Weiping Xie, Xiaohong Zhong, Genhai Zhu